A Pilot Study of Acalabrutinib With Bendamustine/Rituximab Followed by Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
TRIAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [41] Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma
    Fu, Shuangshuang
    Wang, Michael
    Zhao, Hui
    Li, Ruosha
    Lairson, David R.
    Giordano, Sharon H.
    Zhao, Bo
    Du, Xianglin L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (11): : E616 - E623
  • [42] A randomised phase II study of fludarabine/cyclophosphamide +/-rituximab in patients with untreated mantle cell lymphoma
    Rule, S
    Burton, C
    Waleski, J
    Jack, A
    Seymour, J
    ANNALS OF ONCOLOGY, 2005, 16 : 95 - 95
  • [43] Is rituximab retro in mantle cell lymphoma?
    Ryan, Christine E.
    Cohen, Jonathon B.
    BLOOD, 2024, 144 (03) : 241 - 243
  • [44] Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation
    Visco, Carlo
    Finotto, Silvia
    Zambello, Renato
    Paolini, Rossella
    Menin, Andrea
    Zanotti, Roberta
    Zaja, Francesco
    Semenzato, Gianpietro
    Pizzolo, Giovanni
    D'Amore, Emanuele S. G.
    Rodeghiero, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) : 1442 - 1449
  • [45] A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP plus /- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma
    Wang, Hui
    Xing, Lijie
    Liu, Dan
    Wei, Haichen
    Lu, Ke
    He, Qiang
    Xie, Linna
    Ma, Ji
    Qiu, Lugui
    Li, Zengjun
    BLOOD, 2024, 144 : 6307 - 6308
  • [46] Phase 2 Trial of Bortezomib in Combination With Rituximab Plus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Alternating With Bortezomib, Rituximab, Methotrexate, and Cytarabine for Untreated Mantle Cell Lymphoma
    Romaguera, Jorge E.
    Wang, Michael
    Feng, Lei
    Fayad, Luis E.
    Hagemeister, Frederick
    McLaughlin, Peter
    Rodriguez, M. Alma
    Fanale, Michelle
    Orlowski, Robert
    Kwak, Larry W.
    Neelapu, Sattva
    Oki, Yasuhiro
    Pro, Barbara
    Younes, Anas
    Samaniego, Felipe
    Fowler, Nathan
    Hartig, Kimberly
    Valentinetti, Marisa
    Smith, Judy
    Ford, Peggy
    Naig, Adam
    Medeiros, L. Jeffrey
    Kantarjian, Hagop M.
    Goy, Andre
    CANCER, 2018, 124 (12) : 2561 - 2569
  • [47] Results of a pilot trial of fludarabine, mitoxantrone and rituximab in mantle cell lymphoma
    Mohrbacher, A
    Khan, AU
    Tulpule, A
    Espina, BM
    Berman, N
    Mark, L
    Douer, D
    Feinstein, DI
    Levine, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 606S - 606S
  • [48] Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance
    D'Alo, Francesco
    Malafronte, Rosalia
    Piludu, Francesca
    Bellesi, Silvia
    Cuccaro, Annarosa
    Maiolo, Elena
    Modoni, Anna
    Leccisotti, Lucia
    Macis, Giuseppe
    Mores, Nadia
    De Stefano, Valerio
    Hohaus, Stefan
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : E138 - E142
  • [49] Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL).
    Dreyling, martin H.
    Tam, Constantine Si Lun
    Wang, Michael
    Smith, Stephen Douglas
    Ladetto, Marco
    Huang, Huiqiang
    Elstrom, Rebecca L.
    Co, Melannie
    Holmgren, Eric
    Huang, Jane
    Gouill, Steven Le
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial
    Phillips, Tycel
    Wang, Michael
    Robak, Tadeusz
    Gallinson, David
    Stevens, Don
    Patel, Krish
    Ramadan, Safaa
    Wun, Chuan-Chuan
    Jurczak, Wojciech
    Smith, Stephen D.
    HAEMATOLOGICA, 2025, 110 (03) : 715 - 724
12345